Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1315496-38-8

1315496-38-8 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1315496-38-8 Structure

  • Basic information

    1. Product Name: N4-(1-benzylpiperidin-4-yl)-1-(phenylsulfonyl)-1H-pyrrolo-[2,3-b]pyridine-4,5-diamine
    2. Synonyms: N4-(1-benzylpiperidin-4-yl)-1-(phenylsulfonyl)-1H-pyrrolo-[2,3-b]pyridine-4,5-diamine
    3. CAS NO:1315496-38-8
    4. Molecular Formula:
    5. Molecular Weight: 461.588
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1315496-38-8.mol
    9. Article Data: 3

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: N4-(1-benzylpiperidin-4-yl)-1-(phenylsulfonyl)-1H-pyrrolo-[2,3-b]pyridine-4,5-diamine(CAS DataBase Reference)
    10. NIST Chemistry Reference: N4-(1-benzylpiperidin-4-yl)-1-(phenylsulfonyl)-1H-pyrrolo-[2,3-b]pyridine-4,5-diamine(1315496-38-8)
    11. EPA Substance Registry System: N4-(1-benzylpiperidin-4-yl)-1-(phenylsulfonyl)-1H-pyrrolo-[2,3-b]pyridine-4,5-diamine(1315496-38-8)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1315496-38-8(Hazardous Substances Data)

1315496-38-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1315496-38-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,5,4,9 and 6 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1315496-38:
(9*1)+(8*3)+(7*1)+(6*5)+(5*4)+(4*9)+(3*6)+(2*3)+(1*8)=158
158 % 10 = 8
So 1315496-38-8 is a valid CAS Registry Number.

1315496-38-8Relevant articles and documents

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2

Zak, Mark,Mendonca, Rohan,Balazs, Mercedesz,Barrett, Kathy,Bergeron, Philippe,Blair, Wade S.,Chang, Christine,Deshmukh, Gauri,Devoss, Jason,Dragovich, Peter S.,Eigenbrot, Charles,Ghilardi, Nico,Gibbons, Paul,Gradl, Stefan,Hamman, Chris,Hanan, Emily J.,Harstad, Eric,Hewitt, Peter R.,Hurley, Christopher A.,Jin, Tian,Johnson, Adam,Johnson, Tony,Kenny, Jane R.,Koehler, Michael F. T.,Bir Kohli, Pawan,Kulagowski, Janusz J.,Labadie, Sharada,Liao, Jiangpeng,Liimatta, Marya,Lin, Zhonghua,Lupardus, Patrick J.,Maxey, Robert J.,Murray, Jeremy M.,Pulk, Rebecca,Rodriguez, Madeleine,Savage, Scott,Shia, Steven,Steffek, Micah,Ubhayakar, Savita,Ultsch, Mark,Van Abbema, Anne,Ward, Stuart I.,Xiao, Ling,Xiao, Yisong

, p. 6176 - 6193 (2012/09/07)

Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. The C-2 methyl substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compound 3 but also notable JAK1 vs JAK2 selectivity (20-fold and >33-fold in biochemical and cell-based assays, respectively). Features of the X-ray structures of 4 in complex with both JAK1 and JAK2 are delineated. Efforts to improve the in vitro and in vivo ADME properties of 4 while maintaining JAK1 selectivity are described, culminating in the discovery of a highly optimized and balanced inhibitor (20). Details of the biological characterization of 20 are disclosed including JAK1 vs JAK2 selectivity levels, preclinical in vivo PK profiles, performance in an in vivo JAK1-mediated PK/PD model, and attributes of an X-ray structure in complex with JAK1.

TRICYCLIC PYRAZINONE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JANUS KINASE INHIBITORS

-

Page/Page column 62; 105, (2012/07/13)

The invention provides novel compounds of formula I having the general formula (I) wherein X, R1, R2, R3 and R5 are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1315496-38-8